ASX - By Stock
|
PAA |
Re:
Ann: AGM Date & Director Nominations Closing Date for AGM
|
|
ma420
|
17 |
4.7K |
3 |
06/08/24 |
06/08/24 |
ASX - By Stock
|
17
|
4.7K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
911 |
317K |
1 |
06/08/24 |
06/08/24 |
ASX - By Stock
|
911
|
317K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
911 |
317K |
1 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
911
|
317K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
7 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
555
|
219K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
911 |
317K |
6 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
911
|
317K
|
6
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
212 |
118K |
8 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
212
|
118K
|
8
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
212 |
118K |
13 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
212
|
118K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
911 |
317K |
7 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
911
|
317K
|
7
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
2 |
05/08/24 |
05/08/24 |
General
|
11K
|
4.0M
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
655 |
235K |
10 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
655
|
235K
|
10
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Change of Director's Interest Notice - Biggin
|
|
ma420
|
1 |
957 |
9 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
1
|
957
|
9
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Proposed issue of securities - SNT
|
|
ma420
|
36 |
7.9K |
5 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
36
|
7.9K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Proposed issue of securities - SNT
|
|
ma420
|
36 |
7.9K |
4 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
36
|
7.9K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
30K |
6 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
117
|
30K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
8 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
81
|
22K
|
8
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
655 |
235K |
5 |
04/08/24 |
04/08/24 |
ASX - By Stock
|
655
|
235K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
655 |
235K |
24 |
04/08/24 |
04/08/24 |
ASX - By Stock
|
655
|
235K
|
24
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
4 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
555
|
219K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
13 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
555
|
219K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
16 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
555
|
219K
|
16
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
3 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
555
|
219K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
1 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
555
|
219K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
14 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
555
|
219K
|
14
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
9 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
555
|
219K
|
9
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Placement & ANREO to raise up to 13.6m
|
|
ma420
|
11 |
4.0K |
1 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
11
|
4.0K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Change of Director's Interest Notice - Taylor
|
|
ma420
|
6 |
1.8K |
7 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
6
|
1.8K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
12 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
555
|
219K
|
12
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
8 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
555
|
219K
|
8
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Placement & ANREO to raise up to 13.6m
|
|
ma420
|
11 |
4.0K |
4 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
11
|
4.0K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
32K |
8 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
32K
|
8
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
21 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
555
|
219K
|
21
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Application for quotation of securities - CU6
|
|
ma420
|
5 |
1.8K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
5
|
1.8K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
32K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
32K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
12 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
555
|
219K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
6 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
22K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.5K |
0 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
21
|
6.5K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.5K |
3 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
21
|
6.5K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
29 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
22K
|
29
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
13K |
0 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
13K
|
0
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
13K |
1 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
13K
|
1
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
13K |
9 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
13K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
655 |
235K |
26 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
655
|
235K
|
26
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.5K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.5K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
555 |
219K |
18 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
555
|
219K
|
18
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Phase 2 blood cancer trial fully recruited
|
|
ma420
|
21 |
6.1K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.1K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
400 |
146K |
6 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
400
|
146K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
32K |
22 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
32K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
21 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
81
|
22K
|
21
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.5K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.5K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.5K |
23 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.5K
|
23
|
|